Alternatives to Paxlovid If You Can't Fill Your COVID-19 Prescription

You tested positive for COVID-19 and your doctor prescribed Paxlovid. Then your pharmacy delivered the news: out of stock. Or maybe you have a drug interaction that rules out Paxlovid entirely. Either way, you still have COVID-19 and you need treatment — fast.

The good news: Paxlovid isn't your only option. Before giving up, try medfinder to search for Paxlovid at pharmacies near you — you might be surprised. But if Paxlovid truly isn't available or isn't right for you, here are the alternatives.

First: Why Is Paxlovid the Preferred Treatment?

Paxlovid (nirmatrelvir/ritonavir) is FDA-approved and remains the first-line oral antiviral for mild-to-moderate COVID-19 in adults at high risk for severe disease. Clinical trials showed it reduced the risk of hospitalization or death by approximately 89% compared to placebo when started within three days of symptom onset. Its oral form (pills, taken at home) makes it convenient for outpatient use. However, it has significant drug interaction risks due to its ritonavir component, and pharmacy-level stockouts occur during COVID surges.

Alternative 1: Remdesivir (Veklury)

Remdesivir (brand name Veklury), made by Gilead Sciences, is FDA-approved for treatment of COVID-19 in both hospitalized and some non-hospitalized patients. For outpatient use, it's administered as an IV infusion once daily for three consecutive days.

• How it works: Blocks the RNA polymerase enzyme the SARS-CoV-2 virus uses to copy its genetic material, halting replication.
• Cost: Approximately $2,000–$3,000 for a three-day course (plus facility/administration fees). Covered by most insurance including Medicare Part B (since it's IV-administered). Gilead's Advancing Access program offers financial assistance; call 1-800-226-2056.
• Best for: Patients with significant drug interactions that preclude Paxlovid; patients with kidney or liver impairment; patients who can't take oral medications reliably.
• Downside: Requires three separate in-person infusion visits, which is inconvenient when you're sick. Not available at regular retail pharmacies — requires an infusion center or outpatient clinic.

Alternative 2: Xocova (Ensitrelvir)

Xocova (ensitrelvir fumaric acid), developed by Shionogi, was FDA-approved in June 2026. It is a SARS-CoV-2 main protease inhibitor — similar mechanism to the nirmatrelvir component in Paxlovid — but unlike Paxlovid, it does not require ritonavir as a pharmacokinetic booster. This means significantly fewer drug interactions.

• FDA indication: Post-exposure prophylaxis — preventing COVID-19 after close contact with an infected person.
• Availability: Newly available as of June 2026; pharmacy distribution is still building. Check with your provider.
• Best for: Patients who were recently exposed to COVID-19 and want to prevent infection; patients for whom Paxlovid's drug interactions are a concern.

Alternative 3: Molnupiravir (Lagevrio)

Molnupiravir (Lagevrio) was an oral antiviral available under Emergency Use Authorization for adults with COVID-19. It works by introducing errors into the virus's genetic code during replication, preventing it from making viable copies. However, commercial availability has become very limited in 2026, as government-purchased supplies expired in early 2025.

• Efficacy vs. Paxlovid: Clinical trials showed approximately 30% reduction in hospitalization, compared to Paxlovid's ~89%. NIH guidelines consider it a second-line option.
• Advantages: Fewer drug interactions than Paxlovid; oral form; suitable for patients who can't take Paxlovid due to drug interactions or contraindications.
• Not for: Patients under 18 years old (not authorized for pediatric use); not FDA-approved for any indication (EUA only).

38,004+ patients found their medications in stock

38K+

Find Paxlovid In Stock Today →

When Is Supportive Care the Right Choice?

For low-risk, vaccinated, healthy adults with mild COVID-19, IDSA guidelines suggest antiviral treatment may not provide meaningful benefit (estimated hospitalization risk ≤0.5%). In these cases, supportive care — rest, hydration, acetaminophen or ibuprofen for fever and discomfort — may be appropriate. Always discuss your individual risk profile with your doctor before deciding antiviral treatment isn't needed.

Why Paxlovid's Drug Interactions Matter for Choosing an Alternative

Paxlovid's ritonavir component is a potent CYP3A4 inhibitor, meaning it interacts with a wide range of common medications. Patients on immunosuppressants (tacrolimus, cyclosporine), certain heart medications (amiodarone, statins), blood thinners, or some antibiotics may not be able to take Paxlovid safely. For these patients, Remdesivir, Molnupiravir, or supportive care may be more appropriate — a decision that should be made with your prescribing provider.

Skip the calls, skip the stress.

Find Paxlovid In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Comparison Summary

• Paxlovid: ~89% reduction in hospitalization; oral; first-line; many drug interactions
• Remdesivir (Veklury): Strong efficacy; FDA-approved; IV infusion over 3 days; requires clinic visits
• Xocova (Ensitrelvir): FDA-approved June 2026 for post-exposure prophylaxis; fewer drug interactions; still building availability
• Molnupiravir (Lagevrio): ~30% reduction in hospitalization; oral; fewer drug interactions; limited commercial availability in 2026

Act Fast — And Don't Give Up on Paxlovid First

If your first pharmacy is out of Paxlovid, don't give up. Stock is often available at nearby pharmacies, particularly hospital outpatient locations. Use medfinder to search a wide area before pivoting to alternatives. If you do need to switch, do it quickly — the five-day treatment window applies to all SARS-CoV-2 antivirals. For a step-by-step guide to locating COVID-19 antiviral treatment, see how to find SARS-CoV-2 antiviral treatment in stock near you.